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Abstract: Vaccines could be a crucial component of
efforts to eradicate malaria. Current attempts to develop
malaria vaccines are primarily focused on Plasmodium
falciparum and are directed towards reducing morbidity
and mortality. Continued support for these efforts is
essential, but if malaria vaccines are to be used as part of a
repertoire of tools for elimination or eradication of
malaria, they will need to have an impact on malaria
transmission. We introduce the concept of ‘‘vaccines that
interrupt malaria transmission’’ (VIMT), which includes not
only ‘‘classical’’ transmission-blocking vaccines that target
the sexual and mosquito stages but also pre-erythrocytic
and asexual stage vaccines that have an effect on
transmission. VIMT may also include vaccines that target
the vector to disrupt parasite development in the
mosquito. Importantly, if eradication is to be achieved,
malaria vaccine development efforts will need to target
other malaria parasite species, especially Plasmodium
vivax, where novel therapeutic vaccines against hypno-
zoites or preventive vaccines with effect against multiple
stages could have enormous impact. A target product
profile (TPP) for VIMT is proposed and a research agenda
to address current knowledge gaps and develop tools
necessary for design and development of VIMT is
presented.
Introduction
Vaccines are the most cost-effective tools for public health and
have been instrumental in previous elimination campaigns against
smallpox [1], polio [2], and measles [3,4]. Vaccines have also been
useful for sustained control of diseases such as neonatal tetanus [5],
and vaccines such as Haemophilus influenzae type b conjugate
vaccine have the potential to lead to elimination in some settings
[6].
Here, we discuss the research and development agenda for the
development of vaccines that can serve as key components of a
future arsenal of tools to eradicate malaria. Current efforts to
develop malaria vaccines are primarily directed towards reducing
the morbidity and mortality that are associated with malaria and
focus on P. falciparum. For example, the Malaria Vaccine Roadmap
[7] has a strategic goal of developing a vaccine with 80%
protective efficacy against P. falciparum by 2020. However, if
malaria vaccines are to contribute to programs for malaria
elimination, they will need to have an impact on malaria
transmission. The scientific and ethical basis for the development
of vaccines referred to as transmission-blocking vaccines (TBVs)
that specifically target malaria sexual stage antigens with the goal
of having an impact on transmission has been described previously
[8,9]. Here, we refocus attention on the development of vaccines
that can be used in concert with other malaria control
interventions to interrupt malaria transmission and eventually
contribute to the eradication of this disease. We also recommend
that vaccine development efforts need to pay attention to
Plasmodium species other than P. falciparum, especially Plasmodium
vivax, if malaria eradication is to be achieved.
Rationale of the Proposed malERA Approach to
Development of Malaria Vaccines
First, we introduce the broad concept of VIMT. VIMT may be
composed of one or more of the following components: classical
TBVs that target sexual and mosquito stage parasite antigens;
highly effective pre-erythrocytic vaccines that reduce asexual and
sexual stage parasite prevalence rates; highly effective asexual
erythrocytic stage vaccines that inhibit multiplication of asexual
stage parasites efficiently to reduce blood-stage parasite densities
and have an impact on malaria transmission; and vaccines that
target vector antigens to disrupt parasite development in the
vector. It seems obvious that a highly effective pre-erythrocytic
vaccine that prevents erythrocytic stage infection will reduce
transmission, but the effect of partially effective pre-erythrocytic or
asexual blood-stage vaccines on individual infectivity needs
investigation. A successful VIMT must primarily reduce malaria
transmission. However, VIMTs that include pre-erythrocytic and/
or asexual blood-stage vaccine components may also provide
individuals with protection against malaria. Such VIMT would
also protect the population against epidemic spread following
reintroduction of malaria after elimination, an important charac-
teristic given that the gains accrued through many years of
elimination can be rapidly reversed if malaria is reintroduced to a
population with no antimalarial immunity [10].
Second, the observed impact of concerted nonvaccine malaria
control efforts on transmission dynamics in several malaria-
endemic regions has shown that high-intensity transmission
settings (entomological inoculation rate, EIR .50) can be
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,10) [11,12]. Implementation of VIMT together with such
control efforts may successfully drive down transmission rates to
reduce the effective reproduction rate (Reffective) to below 1.0.
Third, the consultative group introduces the concept of a
detailed TPP for this class of vaccines and urges that novel clinical
development methods and approaches be considered to shorten
the time to VIMT registration and implementation.
Fourth, the consultative group lays out a detailed research
agenda that must be developed, funded, and implemented in
parallel with VIMT development efforts. This agenda includes
development of critical tools that will be required to register and
implement such a vaccine. In particular, we identify the need to
develop robust assays to measure biologically relevant transmis-
sion-blocking activities at the individual level that are validated as
surrogates of reductions in transmission rates at the population
level. If this goal is achieved, such assays could become the key tool
for measurement of primary vaccine efficacy endpoints in
conditional registration trials, thereby simplifying the clinical
development program.
Finally, the consultative group considers that interested
industrial partners should be identified early on in development,
because expertise in applied immunology, vaccinology, product
development, manufacturing, and regulatory activities is concen-
trated within industry and will play an essential role in the
successful development of VIMT. In addition, it will be important
to engage with regulatory agencies to define efficient yet sound
regulatory strategies to develop and register new tools that can
meet the needs of global malaria elimination and eradication
efforts.
TPP for VIMT
A TPP is an industry-standard tool that gives clear guidance on
the critical characteristics of a candidate product under develop-
ment. TPPs are developed early in the development process and
ensure that research and development efforts are focused on those
activities that are necessary to develop a product that will meet the
needs of end users. Table 1 presents a TPP for VIMT. For each
characteristic in this TPP, we propose a ‘‘desired target’’
(aspirational) and a ‘‘minimally acceptable target’’ (must achieve).
A vaccine candidate that does not meet or exceed most, if not all,
of the minimally acceptable targets is likely to have a significantly
reduced likelihood of successful introduction and uptake.
P. falciparum and P. vivax are the two most common Plasmodium
species that cause human malaria. P. falciparum is responsible for
most malaria-related deaths. As a result, previous efforts to
develop vaccines for malaria have focused on P. falciparum, which
causes ,500 million cases of malaria annually and is critically
important for Africa. However, P. vivax causes significant
morbidity in other regions of the world including South and
Southeast Asia and Latin America with around 75–90 million
cases of P. vivax malaria reported annually [13]. Recent clinical
epidemiology studies have confirmed that P. vivax can cause severe
disease and may also contribute to malaria-associated mortality
[14–17]. Efforts to eliminate malaria outside Africa must therefore
address both parasite species. Ideally, VIMT should reduce
transmission rates so that Reffective for both P. falciparum and P.
vivax is driven to less than 1 and should provide protection against
clinical malaria caused by both parasite species. At a minimum
(and possibly more realistically), VIMT should achieve reduction
of transmission rates (Reffective ,1) of at least all P. falciparum strains
leading to elimination of P. falciparum when used in conjunction
with other control measures in elimination/eradication cam-
paigns.
As better control is achieved, exposure to malaria parasites will
decrease and ‘‘naturally acquired’’ immunity may play a
diminished role. The mechanisms of clinical immunity observed
in populations under high exposure may have little relevance as,
increasingly, most infections will occur in people with little
previous exposure. Therefore, our TPP specifies that a vaccine
intended to interrupt transmission should not presume an age-
specific risk or preexisting state of immunity against malaria
disease or transmission. It is likely that VIMT may need to be
implemented in the entire population.
Other ideal as well as minimally acceptable parameters for
VIMT include product presentation, dosage, storage, and
coadministration with other immunizations. These parameters
are detailed in Table 1.
Research in Support of Development of VIMT
Much of the ongoing work on malaria vaccine development has
focused on the development of interventions that address disease
manifestations and the work has been primarily focused on P.
falciparum. To support the development of vaccines and other tools
necessary for malaria eradication new dimensions need to be
added to the fundamental research portfolio (see [18] also). For
example, P. vivax needs to be added, and efforts need to be
refocused on the development of vaccines that target sexual and
mosquito stages of malaria parasites, which should interrupt
transmission. The expanded portfolio also needs to include more
research on vaccine delivery systems and adjuvants, the transmis-
sion dynamics and population biology of malaria parasites, and
measurements of transmission rates.
Human Malaria Parasites beyond P. falciparum
VIMT that target P. falciparum alone are likely to be deployed
only in regions where P. falciparum is the species predominantly
responsible for malaria. Regions where P. vivax is responsible for a
significant proportion of the malaria burden will require VIMT
that target both species.
Control efforts in regions where P. falciparum and P. vivax both
occur indicate that it is more difficult to reduce transmission of P.
vivax than of P. falciparum This increased difficulty is attributed in
part to the development of gametocytes earlier during blood-stage
Summary Points
N Vaccines for malaria eradication need to have an impact
on transmission rather than focusing on mortality and
morbidity reduction alone
N Vaccines that interrupt malaria transmission (VIMT) may
target many stages of the parasite’s life cycle, not just
the sexual and mosquito stages as in classical blocking
vaccines and multiple plasmodium species, in particular
Plasmodium vivax
N Novel vaccine delivery approaches and adjuvants need
to be developed
N Other priority areas for research and development
include the development of tools to measure transmis-
sion rates and the development of robust assays of
functional immune responses in individuals, which could
inform vaccine development
N A better understanding of the dynamics between the
multiplication of parasites, gametocytogenesis, and
malaria transmission rates in populations is also needed
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allows transmission before clinical symptoms are apparent. Other
factors contributing to the difficulty of reducing P. vivax
transmission include: the development of hypnozoites that remain
latent in hepatocytes and lead to blood-stage infections months or
even years later; transmission by outdoor biting mosquitoes; and
the ability of P. vivax to complete its life cycle in a wider range of
climatic and ecological conditions than P. falciparum. Because of
these unique features of P. vivax, traditional malaria control efforts
such as vector control, bednets, and early detection and treatment
Table 1. TPP VIMT.
Item Desired Target Minimally Acceptable Target
Indication The candidate vaccine is indicated for active immunization
of individuals for protection against P. falciparum and P. vivax
malaria and to achieve reduction of transmission rates of all
strains of P. falciparum and P. vivax so that Reffective ,1
a.
The candidate vaccine is indicated for active immunization of
individuals to achieve reduction of transmission rates of all
strains of P. falciparum so that Reffective ,1
a in conjunction with
other control measures.
Target populations The vaccine can be administered to all age groups and
populations, including pregnant women, persons with
immunodeficiencies, malnourished individuals, or
otherwise high risk populations.
The vaccine can be administered to otherwise healthy persons
who may transmit malaria, including infants, children,
adolescents, and adults in malaria-endemic regions.
Route of administration The vaccine is administered orally or by intramuscular or
subcutaneous injection or by other innovative device.
The vaccine is administered by intramuscular, intradermal
subcutaneous injection, or an innovative device.
Product presentation The vaccine is available in a single dose auto-disposable
compact prefilled device. Low multidose presentations
(ten doses/vial) are also needed.
The vaccine is provided as a lyophilized or liquid product in
single dose vials or an auto-disposable compact prefilled
device; or low-dosage (two doses) vials that may be
accompanied by a separate paired vial containing adjuvant/
diluents. A suitable preservative may be required for multidose
vials. Reconstitution may be required prior to administration.
Dosage schedule A single dose vaccine that can be administered by either
mass administration or clinic-based programs. Booster
dose may be required after 2 years.
A maximum of two to three doses of vaccine that can be
administered according to a schedule feasible for both mass
administration and clinical-based programs. A booster dose
may be necessary 4–6 months after the second dose and after 2
years.
Warnings and precautions/
pregnancy and lactation
The vaccine has a safety and reactogenicity profile
comparable to hepatitis B vaccine. The vaccine can be
safely administered to pregnant women. There should
be no increased risk of autoimmune or other chronic
diseases related to vaccination.
In young children, the vaccine has a similar safety and
reactogenicity profile to currently administered combination
vaccines such as DTPwHepBHib administered through EPI. In
adults, the vaccine has a similar safety and reactogenicity
profile as hepatitis B vaccine or tetanus toxoid. The vaccine can
be safely administered to pregnant women. There should be no
increased risk of autoimmune or other chronic diseases related
to vaccination.
Expected efficacy Reduces Reffective below 1.0 in a malaria-endemic
population and provides protection against P. falciparum
and P. vivax for at least 2 years.
When used in a malaria-endemic population that employs ITNs,
IRS, or other malaria control tools, further reduces Reffective to
below 1.0 for at least 1 year.
Coadministration The vaccine can be coadministered with any licensed
vaccine without a clinically significant interaction in relation
to safety or immunogenicity. For use in infants with other
EPI vaccines, specific coadministration studies must be
completed to demonstrate the noninferiority of responses
to EPI vaccines given in coadministration.
The vaccine will be given as a stand-alone product not
coadministered with other vaccines.
Shelf life The product must have a minimum shelf life of 36 months
and a Vaccine Vial Monitor should be attached (see [54]).
The product must have a shelf life of at least 24 months and a
Vaccine Vial Monitor should be attached (see [54]).
Storage The product must be stable at ambient temperature
and withstand freeze thawing.
At a minimum, vaccines should be stable at refrigerated storage
temperatures (2–8uC). New vaccines should be formulated to
maximize heat stability to improve effectiveness in light of the
challenges faced in distributing vaccines in developing
countries. Vaccine vial monitors should be included on all
vaccines in accordance with the WHO and UNICEF joint policy
statement and the WHO prequalification standards for vaccines.
In case of live, attenuated sporozoite vaccines, vaccine should
be stable at 270uC.
Vaccine vial monitors should be included on all vaccines in
accordance with the WHO and UNICEF joint policy statement
and the WHO prequalification standards for vaccines.
Product registration and
WHO prequalification
Product must be WHO prequalified (see [54]) and
registered with EMEA and FDA.
Conditional registration or recommendation by WHO or
competent NRA followed by a large impact study in phase IV.
Product must be WHO prequalified (see [55]).
aReffective, number of individuals who can be infected from a single untreated malaria case in an endemic area.
EMEA, European Medicines Agency; EPI Expanded Programme on Immunization; FDA, US Food and Drug Administration; NRA, National Regulatory Agency; IRS, indoor
residual insecticide spraying; ITN, insecticide-treated net.
doi:10.1371/journal.pmed.1000398.t001
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lasting immune responses that prevent infection or inhibit
gametocyte development or transmission of sexual stages are
likely to be more effective tools for control of P. vivax. Given that
latent hypnozoites can lead to blood-stage infections years after an
infective bite, it may be necessary to continue deployment of
VIMT that target P. vivax after elimination is achieved. An
alternative would be to develop vaccine components that can
target and eliminate hypnozoites. Design of such vaccines will
require better understanding of the unique aspects of the biology
of P. vivax hypnozoites at the molecular level.
Other Plasmodium species such as Plasmodium ovale and Plasmodium
malariae account for less than 5% of malaria cases worldwide.
Natural infection of humans by Plasmodium knowlesi has recently
been reported [19,20]. Thus, we need to be prepared for the
emergence of new Plasmodium species that can cause human
malaria. It remains to be seen whether these parasite species will
survive once efforts to eliminate P. falciparum and P. vivax are
successful. For now, then, efforts should be focused on developing
VIMT for P. falciparum and P. vivax malaria, but it will be
important to monitor the epidemiology of P. ovale, P. malariae, and
P. knowlesi as elimination of P. falciparum and P. vivax progresses.
Decisions to support development of vaccines that block
transmission of these parasite species may need to be made in
the future.
Discovery Research
Malaria parasites have a complex life cycle during which they
infect humans and are transmitted by Anopheline mosquitoes.
The successful completion of the parasite life cycle requires specific
molecular interactions between the parasite and various host and
vector tissues. A clear understanding of the molecular interactions
that mediate invasion of hepatocytes by Plasmodium sporozoites,
invasion of erythrocytes by Plasmodium merozoites, and traversal of
mosquito midgut epithelium by Plasmodium ookinetes may allow
the development of strategies to target these key interactions and
disrupt the parasite life cycle thereby reducing malaria transmis-
sion rates. It may be necessary to combine components that target
different stages of malaria parasites to achieve synergistic effects
that provide protection and reduce malaria transmission rates. For
example, partially effective pre-erythrocytic and blood-stage
components may not have any effect on transmission but the
addition of such partially effective components to classical TBVs
might allow the development of a multicomponent VIMT that can
reduce malaria transmission as well as provide protection against
malaria.
Targeting the Sexual and Mosquito Stages
Gametocytes are the source of the epidemiologically important
transmission of all malaria parasites. In P. falciparum, recent work
has demonstrated that the developmental switch from asexual
replication to sexual stage development occurs at the ring stage
and that all schizonts from that ring parasite are committed to
form gametocytes upon invasion of new red blood cells [21]. P.
falciparum then undergoes sequential development through five
distinct morphological stages to form mature male and female
gametocytes. Within the mosquito midgut, mature male and
female gametes are released and fertilization occurs to form a
zygote. The resultant motile ookinete passes through the midgut
wall, undergoes reduction division, and forms an oocyst. Each step
in this developmental pathway involves unique processes,
including the transcription of specific genes, the expression of
specific proteins, the upregulation of specific biochemical path-
ways, and the formation of new morphological structures.
Understanding the regulation of this developmental process could
be the key to developing new interventions that target sexual and
mosquito stages to interrupt transmission. For example, direct
targeting of the developing gametocyte has the potential advantage
of targeting a small subset of infected red blood cells that express
proteins or pathways specific to parasite sexual development. A
drug or a vaccine that could inhibit the initial switch to sexual
development, coupled with a vaccine that targets gamete antigens
might provide a powerful combinatorial approach to reduce
transmission (also see [22]).
There is a large body of work on the key antigens on the surface
of gametes of both P. falciparum and P. vivax [9]. Several of these
antigens have been tested in animal models as transmission-
blocking vaccines, at least two which have been tested in humans
[23,24]. A phase I trial of the P. vivax ookinete surface antigen
Pvs25 formulated with Alhydrogel demonstrated acceptable safety
and reactogenicity with induction of anti-Pvs25 immunoglobulin
G (IgG) with functional transmission-blocking activity in a
membrane-feeding assay. However, these data suggest that a
more immunogenic formulation would be desirable to achieve
higher transmission-blocking activity [23]. More recently, a trial of
ISA51 formulations of Pvs25 and Pfs25 was terminated because
of unacceptable reactogenicity [24]. The expression of correctly
folded Pfs48/45 gametocyte surface antigen has recently resulted
in a demonstration of transmission-reducing activity in sera from
immunized animals [25,26].
Targeting Pre-erythrocytic and Asexual Stages
Highly effective pre-erythrocytic stage vaccines can, in princi-
ple, reduce the prevalence of blood-stage parasites, including both
the asexual stages and the gametocytes. Such vaccines can provide
protection against malaria and reduce malaria transmission.
Immunization with irradiated sporozoites has elicited complete
protection against sporozoite challenge in experimental animal
models and in humans. Thus, in principle, it should be possible to
target pre-erythrocyte stage antigens to elicit complete protection
against parasite infection. Protective immune mechanisms elicited
by irradiated sporozoites are not well understood but are thought
to include antibody responses against sporozoite antigens that
prevent hepatocyte infection, and cellular responses that clear
infected hepatocytes. Better understanding of the correlates of
immunity elicited by immunization with irradiated sporozoites
could guide the development of highly effective pre-erythrocytic
subunit vaccines that both provide protection and reduce parasite
transmission. A recombinant vaccine based on the circumspor-
ozoite protein, RTS,S has been shown to elicit partial protection
against P. falciparum infection [27,28]. It seems unlikely, however,
that RTS,S will have significant impact on gametocyte prevalence
or affect malaria transmission.
Other vaccines based on irradiated sporozoites or genetically
modified attenuated sporozoites have provided protection in
challenge models [29,30]. Such whole organism attenuated
vaccines may provide effective protection against malaria and
significantly reduce parasite transmission. However, considerable
technological challenges in terms of manufacturing, formulation,
and delivery of such attenuated sporozoite vaccines need to be
overcome.
During P. vivax infections, some infected hepatocytes differen-
tiate into latent hypnozoite stages that can yield merozoites after a
long latency period. The biology of hypnozoites is very poorly
understood but the development of drugs or vaccines that can
clear hypnozoites is critical for success of efforts to eradicate P.
vivax [22]. The development of methods for in vitro culture of
hypnozoites could greatly help improve our understanding of this
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application of whole genome approaches such as transcriptomics
and proteomics to the identification of parasite proteins expressed
in hypnozoites. It may be possible to elicit cellular immune
responses against such hypnozoite specific proteins to clear these
latent stages. Vaccines against pre-erythrocytic stages of P. vivax
that are effective against both developing and resident hypnozoites
would be of inestimable benefit in efforts to eliminate P. vivax.
Vaccines based on asexual blood-stage antigens may be effective
at reducing parasite densities and provide protection against
clinical disease but it is not clear whether such vaccines can reduce
malaria transmission rates effectively. Basic research is needed to
understand the dynamics of the relationship between asexual stage
parasite growth, sexual stage parasite densities in blood, and
individual infectivity or transmission efficiency. Recombinant
vaccines based on asexual blood-stage antigens tested in human
clinical trials have not yielded high rates of growth inhibition thus
far and are unlikely to have significant impact on gametocyte
prevalence or infectivity of individuals. Irrespective of whether
vaccines based on asexual blood-stage antigens can reduce sexual
stage parasite densities and reduce transmission, combinations of
asexual blood-stage vaccines with classical TBVs will enable
development of VIMT that provide direct benefit to vaccine
recipients by providing protection against clinical disease in
addition to reducing transmission.
Targeting the Vector to Reduce Malaria Transmission
As described earlier, Plasmodium parasites have an obligatory
development stage in the mosquito during which zygotes
transform into ookinetes that traverse the midgut epithelium to
establish oocysts on the outer wall of the midgut. Attachment and
invasion of the midgut epithelium requires specific interactions
between ookinete surface proteins and midgut receptors. A set of
conserved ‘‘invasion receptors’’ on the midgut of diverse
Anopheline species are used by Plasmodium ookinetes to attach to
the midgut epithelium [31]. Antibodies directed against such
receptors have been shown to block development of oocysts in
membrane-feeding transmission-blocking assays [31]. A vaccine
based on such conserved vector antigens should be effective
against all species of Plasmodium and obviate the need to develop
separate vaccines for different Plasmodium species. Moreover, since
such vaccines target vector antigens, parasite strain diversity,
which has been a major problem for malaria vaccine development,
will be overcome. Such novel strategies will require significant
fundamental research to understand vector-parasite interactions
[32].
Host-Parasite and Vector-Parasite Interactions
Plasmodium sporozoites invade human hepatocytes in a two-step
process. In the first step, sporozoites pass through multiple
hepatocytes by rupturing the plasma membrane of target
hepatocytes [33]. After traversing multiple hepatocytes, sporozo-
ites finally invade target hepatocytes by forming a parasitophorous
vacuole where they multiply and differentiate into merozoites.
Identification of key parasite proteins that mediate the two-step
invasion process could provide functional targets for intervention.
Sporozoite surface proteins such as the circumsporozoite protein
(CSP) and thrombospondin-related protein (TRAP) have been
shown to play a role in hepatocyte binding and invasion [34–37].
Both proteins contain functional cysteine-rich regions that share
homology with thrombospondin and that mediate attachment to
hepatocyte receptors. Antibodies targeting such functional regions
can block hepatocyte invasion. Vaccines that elicit high-titer long-
lasting antibodies against such functional domains might reduce
the prevalence of blood-stage infection effectively. Similarly,
antibodies targeting merozoite antigens such as the 175-kD
erythrocyte binding antigen (EBA175) [38–41], Duffy binding
protein [42], or PfRH proteins [43], which mediate critical
interactions with erythrocyte receptors, can inhibit multiplication
of blood-stage parasites. Ookinete antigens that interact with the
midgut wall to mediate traversal may also be useful as
recombinant malaria vaccine candidates that block parasite
transmission by mosquitoes.
Because processes such as host cell invasion involve multiple
steps, some of the processes highlighted above may be mediated by
multiple pathways that are redundant. As a result, effective
inhibition of host invasion by parasites may require targeting of a
combination of receptor-ligand interactions that mediate invasion.
A clear understanding of the sequence of events and functional
roles of different receptor-ligand interactions will be critical for the
development of vaccines that target multiple steps to provide
synergistic inhibition of invasion and parasite multiplication at
different stages of the parasite life cycle.
It will also be important to develop functional assays that can be
used to evaluate antibody responses against the parasite antigens
that mediate host cell invasion and transmission to mosquitoes.
These functional assays may directly test the inhibitory activity of
antibodies elicited by vaccine candidates against the biological
processes themselves or may be reduced to biophysical or
biochemical assays in which antibodies are tested for inhibition
of functions such as receptor binding or proteolytic cleavage that
are known to mediate the biological processes. Harmonization of
such assays is important so that results from different research
groups are comparable and to facilitate decision making for down-
selection of vaccine candidates during preclinical and clinical
development. Currently, there are no clear correlates of immunity
against pre-erythrocytic and blood-stage parasites. Immuno-assays
can be validated only once a vaccine demonstrates efficacy in a
clinical trial. Once an immune correlate for protection is
identified, it can be used for decision making in clinical
development.
Vaccine Delivery Systems and Adjuvants
The development of subunit vaccines will require the use of
potent adjuvants and/or efficient vaccine delivery systems to elicit
robust and sustainable immune responses. The unavailability of a
wide range of potent adjuvants with a proven safety record in
humans has been a bottleneck in the development of recombinant
protein–based vaccines for malaria. Better understanding of
mechanisms that activate the innate immune system might enable
the design of adjuvants that elicit potent immune responses.
Alternative methods to deliver antigens such as the use of virus-like
particles or prime-boost strategies that use combinations of
different viral vectors (e.g., recombinant adenovirus and modified
vaccine virus–based vectors) or viral vectors and recombinant
proteins have provided effective means to elicit potent immune
responses [44], but further research on vaccine delivery systems is
urgently required for development of effective malaria vaccines.
When the VIMT include multiple components, it will be
important to develop formulations or delivery systems that are
compatible with each component. A clear understanding of the
correlates of protective immunity elicited by each component may
allow the identification and development of a compatible delivery
system or adjuvant formulation for the combination vaccine.
Analysis of candidate vaccine–elicited immune responses in
functional assays will allow optimization of compatible formula-
tions. Importantly, development of multicomponent VIMT may
require collaboration between researchers who have developed the
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licensing arrangements that ensure accessibility of each compo-
nent for commercial development of such multicomponent VIMT.
Understanding Transmission Dynamics and Population
Biology of Malaria Parasites
As campaigns to reduce transmission of malaria are successful, it
will be necessary to understand the changes in parasite population
dynamics and population structure. In particular, it will be
desirable to determine whether specific parasite strains dominate
as the transmission pattern changes and whether this has
implications with regard to antigenic diversity or parasite
virulence. Field trials with P. falciparum blood-stage vaccines have
provided evidence for allele-specific protection, which suggests
that large-scale immunization may lead to the selection of
‘‘vaccine-resistant’’ parasites that can escape immune responses
elicited by the vaccine [45]. A second important question is to
determine whether reemergent parasites have been introduced
from an outside source or whether they are parasites that have
escaped control measures. These two options have very different
implications for intervention strategies during the pre-elimination
stage. Tools to track such parasites will be useful for surveillance as
control efforts move towards eradication.
Measuring Malaria Transmission Rates
A key to the evaluation of vaccines that block transmission will
be the measurement of transmission. The anticipated clinical
outcome of vaccination will be the reduction of transmission in the
community. It is therefore necessary to develop robust and readily
usable tools to evaluate transmission levels in various epidemio-
logical settings ranging from high transmission areas to areas of
very low prevalence and transmission. In particular, as various
malaria control measures are introduced, the transmission
dynamics will change and robust evaluation of transmission will
be challenging. Harmonization of existing tools for measurement
of transmission rates is a high priority [46,47].
It is particularly important to be able to measure the effect on
infectivity of an individual after vaccination with either a pre-
erythrocytic or a blood-stage vaccine, and to understand the
relation of this result to an effect on transmission in the
community. Clinical efficacy trials of such vaccines have tended
to focus on their impact on blood-stage infection or clinical
disease; the impact of such vaccines on transmission remains to be
determined. An important aspect of strategic thinking around
malaria vaccines in years to come will be a greater emphasis on the
evaluation of the impact of all classes of vaccines on transmission.
A second priority is the development of markers that define the
infectivity of an individual for mosquitoes. These markers could
include bioassays, serological parameters, or molecular markers.
There is a need for robust models that predict the relationship of
rates of individual infectivity to transmission at the community
level in different epidemiological settings. Once this relationship is
established, such markers could be used as surrogates of vaccine
efficacy on transmission at the population level.
Strategies for Product and Clinical Development
of VIMT
Product Development Based on TPP
Once TPPs are defined, they should be used to guide product
development and evaluate the project in terms of achieving desired
goals set for the vaccine candidates. It is important to understand
where the project stands in terms of development. Terminology
should be used appropriately and be in line with the development
phase of the product (Figure 1).
Preclinical feasibility studies are conducted first to validate the
scientific rationale for vaccine design. At this stage of the project,
questions have to be asked that address issues such as whether the
project is likely to achieve the final desired TPP. Numerous
preclinical feasibility studies may be undertaken to assess a variety
of antigens, adjuvants, and delivery systems. Importantly, immune
responses with the experimental vaccine produced at pilot scale
need to be evaluated in animal models, preferably using functional
assays, to validate the concept and progress it to a translational
project stage.
For the translational stage, a significant investment of resources
is necessary, not least because the prototype vaccine must be
produced under current good manufacturing practices. Thus, only
the most promising approaches can be moved into this and later
stages of development. The translational project, which will have a
set of precise go/no-go milestones, drives a research program of
relevance to public health from the preclinical phase, through
phase I trials to evaluate safety, and into phase II trials to evaluate
efficacy. A successful translational project will deliver a vaccine
that should be ready for phase III trials.
A product can be considered as a vaccine candidate once its
manufacturability has been established and it has undergone a
Figure 1. Classification of programs. Image credit: Fusio ´n Creativa.
doi:10.1371/journal.pmed.1000398.g001
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‘‘classical’’ pre-erythrocytic or asexual stage vaccines, this typically
requires either a phase IIa challenge trial or an efficacy trial in an
endemic country. For VIMT, proof of concept may not need to be
established in a malaria-endemic setting, provided that a robust
read-out measurable at the level of the individual vaccinees has
been shown to predict an effect on transmission at the population
level. By this stage the product is fully characterized and will not
change substantially. Major investments will be required, however,
to complete the development program to deliver a viable vaccine
for use in public health programs. Other considerations for a
successful vaccine include the requirement for WHO prequalifi-
cation of the vaccine for use in developing countries, an
understanding in the affected communities of the ethical and
practical issues associated with a long program of testing, and a
significant commitment of the donor community to provide funds
to support country-wide vaccine launches.
Clinical Development and Regulatory Strategy
A vaccine that has an effect on transmission alone may not
provide direct benefit to the individual. Registration pathways for
such a vaccine are therefore likely to be complex, and the licensure
endpoints will require careful consideration and discussion with
regulatory agencies early in the development program. If the
vaccine also provides individual benefit, the regulatory pathway
could well be simpler.
One approach to registration for VIMT is for phase I/II
programs to focus on identification of well-tolerated and
immunogenic vaccine doses and schedules across a wide age
range of vaccine recipients using standard safety assessments and
immunologic readouts tailored for the vaccine candidate being
evaluated. Randomized, controlled phase IIb proof-of-concept
studies should be designed to permit the identification of a suitable
vaccine efficacy endpoint at the individual level that can be
validated for use in phase III trials. This endpoint must be
identified and agreed in advance with regulatory agencies. The
possible endpoints might include: percent reduction in parasite
prevalence, especially gametocyte prevalence; percent reduction in
individual infectivity as measured by percent reduction in oocyst
and sporozoite counts in membrane-feeding assays; and percent
reduction in infected mosquitoes fed on vaccinated volunteers that
can transmit malaria to susceptible volunteers. We recognize that
such efficacy endpoints at the individual level will only be
surrogates for effects on malaria transmission rates at the
population level. Thus, a necessary stage after conditional
registration based on surrogate efficacy data will be definitive
community-scale phase IV trials, which will measure reductions in
effective reproduction rate (Reffective) as a postmarketing commit-
ment.
Alternatively, some experts have argued that it should be
possible to design and conduct cluster-randomized trials to
evaluate the efficacy of VIMT in terms of reductions in
transmission rates in malaria-endemic settings. Measurement of
surrogate efficacy parameters at the individual level using robust
assays in such trials may allow the identification of correlates of
efficacy at the population level. Such an approach would follow
the more traditional route of registering a vaccine after collecting
evidence for efficacy in phase IIb/III trials. Ultimately, it will be
important to study the efficacy of combination of vaccines with
other interventions aimed at reducing transmission.
Decision Making in Development of VIMT
Existing methods for measurement of transmission intensity
need to be harmonized and optimized to ensure that good baseline
estimates are available prior to introduction of a package of
interventions such as drugs and vaccines. Thus, an essential step
will be a consultation process that decides on the relative utility of
assays that assess the infectiousness of individuals [48], that
measure transmission-blocking activity of sera [49] raised against
sexual stage or mosquito antigens, and that consider trial designs
to measure the impact of vaccines targeting any life cycle stage on
malaria transmission [50].
Possible trial designs include community-randomized trials that
use measurement of the reduction in the proportion of gametocyte
carriers, the reduction in the infectiousness of humans to
mosquitoes in individually randomized controlled trials, and the
reduction in infection of humans as endpoints. However, the
development of an assay or trial design that could provide robust,
reproducible data on vaccine impact on transmission without
performing large-scale community-randomized trials would be a
major step forward in increasing efficiencies and timelines.
Many questions will need to be addressed to aid decision
making during development of VIMT. For example, can assays
such as the membrane-feeding assay be validated to meet the
requirements of the International Conference of Harmonization?
If so, what level of reduced infectivity as demonstrated by this
assay is likely to provide community-level reduction in infection?
Questions like these need to be answered so that decisions can be
made about the packages of interventions required to bring the
Reffective below 1 during elimination campaigns. An assessment of
existing modeling work may provide information on this sort of
issue [51,52]. Other questions that will need answering include:
what population coverage and level of transmission-blocking
efficacy should we require from a vaccine intervention before it is
transitioned into elimination campaigns and are there assays other
than the membrane-feeding assay that will be useful in
measurement of infectiousness of humans (for example, nucleic
acid amplification-based assays for gametocytaemia)? Ways will
also need to be found to optimize mosquito-feeding experiments
linked to clinical vaccine trials for decision-making purposes (see
also [53]).
Importantly, every step of the vaccine development, clinical
evaluation, regulatory, and implementation process for VIMT
needs to focus on using the TPP for vaccines and targeting
transmission rather than morbidity during decision making. In
addition, it will be essential to make decisions about the need to
include packages of interventions when evaluating vaccines that
reduce transmission (see also [52]). Decisions will also have to be
made about who should receive VIMT. In endemic regions,
VIMT would be delivered to infants, preferably through the
routine expanded program of immunization and through periodic
campaigns to the rest of the population. In regions of low malaria
transmission, it may not be necessary to immunize the entire
population. Instead it may be more effective to identify and
immunize individuals who are responsible for the majority of the
transmission in the community.
Assessment of interruption of transmission presents novel
challenges and large costs, hence every effort must be made to
find and adopt the most efficient mechanism for assessing efficacy.
For example, could a competent regulatory authority be provided
with sufficiently compelling evidence of the biological interruption
of transmission activity of a vaccine (either prevention of
gamtetocyte production or effects of antisera on transmission to
mosquitoes) to allow registration of a vaccine with an indication
for interruption of transmission at the community level, without
the requirement for large-scale community randomized trial data?
As mentioned earlier, phase IV studies could then follow to
provide the required safety database, and measures of community
PLoS Medicine | www.plosmedicine.org 7 January 2011 | Volume 8 | Issue 1 | e1000398effects on transmission for implementation. Industry involvement
may be critical to successfully drive such a development pathway
for VIMT. It will therefore be important to engage leaders of key
vaccine industries as well as regulatory agencies and ethicists from
affected countries in discussions early in the development pathway.
Conclusions
Vaccines can play a key role in multisectoral efforts to eliminate
and eventually eradicate malaria. Current efforts to develop
malaria vaccines are primarily focused on reducing infection rates,
blocking replication of the parasite in the bloodstream, and the
pathologic effects of the parasite in individuals, thereby reducing
malaria morbidity and mortality in vaccinated individuals. Some
of these vaccines, if highly effective, may also reduce transmission.
These efforts need continued support.
For elimination, it is important to view vaccines for their
potential contribution to reduction of transmission, and to support
additional novel approaches to vaccines that directly target sexual
and mosquito stages for use in malaria control programs. In this
context, we propose the broader concept of VIMT and present an
actionable research and development agenda to develop such
vaccines (Box 1). We also propose that novel product development
and regulatory strategies that reduce the time to market should be
investigated to develop, license, and implement such vaccines.
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